Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

LH and FSH as Diagnostic Tools

Using the Gonadotropins to Separate Primary (Testicular) from Secondary (Central) Hypogonadism

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
N/A (diagnostic analytes); hCG/recombinant gonadotropins are FDA-approved therapeutics

Reference only. Not medical advice.

What can go wrong

The principal hazard is diagnostic shortcutting: omitting LH/FSH can misclassify a man with a treatable pituitary lesion (e.g., a prolactinoma) or a fertility-preservable secondary hypogonadism, leading to inappropriate lifelong exogenous testosterone. Gonadotropin-based therapies themselves are well tolerated but require specialist management.

This is something to take to a clinician. The Atlas can tell you what is known about lh and fsh as diagnostic tools in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are the pituitary's output signals to the testis, and measuring them is the pivotal step that classifies male hypogonadism. The logic is simple feedback: if the testis fails, the pituitary detects low testosterone and shouts louder, so LH and FSH rise (PRIMARY / hypergonadotropic hypogonadism). If the hypothalamus or pituitary fails, the signal never arrives, so LH and FSH are low or inappropriately normal despite low testosterone (SECONDARY / hypogonadotropic hypogonadism). This single fork determines the entire workup, karyotype and testicular evaluation in one direction, pituitary imaging and prolactin in the other, and it dictates whether fertility-preserving treatments even make sense.

Two cheap labs that change everything. LH and FSH tell you WHERE the axis is broken, and therefore what to do.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Classifying hypogonadism as primary vs secondary
  • Triggering the correct downstream workup
  • Selecting fertility-preserving therapy (gonadotropins/SERMs) over exogenous testosterone
  • Detecting exogenous androgen use (suppressed LH/FSH with high T)
Primary (hypergonadotropic)
High LH/FSH: Klinefelter syndrome (47,XXY), prior orchitis, chemotherapy/radiation, testicular trauma, cryptorchidism history
Secondary (hypogonadotropic)
Low/normal LH/FSH: pituitary adenoma, hyperprolactinemia, Kallmann syndrome, opioids, glucocorticoids, severe obesity, exogenous androgens
Mixed / compensated
Borderline patterns requiring repeat morning testing and clinical correlation

How it works

LH binds Leydig-cell LHCGR receptors to stimulate testosterone synthesis; FSH acts on Sertoli cells to support spermatogenesis and stimulate inhibin B (which selectively restrains FSH). Testosterone and estradiol feed back to suppress LH (and to a lesser degree FSH). Therefore the RATIO of gonadotropins to testosterone localizes the lesion: elevated gonadotropins with low T means the testis cannot respond to a maximal central signal; suppressed or inappropriately normal gonadotropins with low T means the central drive itself is deficient. A markedly elevated FSH with low inhibin B specifically points to seminiferous-tubule (spermatogenic) failure.

The clinically decisive fork

This distinction is not academic, it changes treatment direction completely. In PRIMARY hypogonadism the testis is the problem, so endogenous-stimulating therapies (hCG, clomiphene, enclomiphene) will not work, and exogenous testosterone is the usual route (with fertility counseling, since sperm are already compromised). In SECONDARY hypogonadism the testis is presumably capable, so gonadotropin therapy (hCG +/- FSH) or SERMs can restore BOTH testosterone and fertility, and giving plain testosterone instead would needlessly suppress the man's own (recoverable) sperm production. A young man with low T who wants children is exactly the patient for whom skipping LH/FSH and reflexively prescribing testosterone is a consequential error.

What people get wrong

  • Often saidA low testosterone result is enough to start treatment

    ActuallyGuidelines require a repeat morning total T, then LH/FSH to localize the problem. Treating before localizing risks giving the wrong therapy and, in fertility-seeking men, suppressing recoverable sperm production.

  • Often saidLH and FSH are only for fertility doctors

    ActuallyThey are core to every male hypogonadism workup. Suppressed gonadotropins with high testosterone, for instance, is a classic signature of undisclosed exogenous androgen use.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

What we do not know

  • How should 'compensated' hypogonadism (high LH, still-normal T) be managed long term?
  • What gonadotropin thresholds best predict response to fertility-restoring therapy?
  • Can point-of-care LH/FSH improve appropriate triage in telehealth men's-health settings?

At a glance

LH source
Pituitary gonadotrophs; pulsatile, drives Leydig T
FSH source
Pituitary; supports Sertoli cells / spermatogenesis
Primary hypogonadism
Low T + HIGH LH/FSH (e.g., Klinefelter, mumps orchitis)
Secondary hypogonadism
Low T + LOW/normal LH/FSH (e.g., pituitary tumor, opioids, obesity)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about LH and FSH as Diagnostic Tools. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Endocrine Society Clinical Practice Guideline2018

    Recommends confirming low morning testosterone on two occasions, then measuring LH/FSH to distinguish primary from secondary hypogonadism

  • EMAS gonadotropin patterns2010s

    Population characterization of compensated (high LH, normal T) vs secondary patterns and their clinical correlates

  • Inhibin B / FSH spermatogenesis studies2000s

    FSH and inhibin B as markers of seminiferous-tubule function in male-factor infertility